4.7 Article

Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial.

Journal

Journal for ImmunoTherapy of Cancer
Volume 3, Issue Suppl 2, Pages O11

Publisher

Springer Nature
DOI: 10.1186/2051-1426-3-s2-o11

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available